TABLE 1.
Overview of the included cohorts in this study
| Parameter | Discovery | Verification: V cohort |
Evaluation | ||
|---|---|---|---|---|---|
| D1 cohort | D2 cohort | E1 cohort | E2 cohort | ||
| Number | 114 | 59 | 141 | 145 | 187 |
| Gender | |||||
| Male (%) | 54 (47.4) | 31 (52.5) | 85 (60.3) | 108 (74.5) | 107 (57.2) |
| Female (%) | 60 (52.6) | 28 (47.5) | 56 (39.7) | 37 (25.5) | 80 (42.8) |
| Age | |||||
| 18–60 (%) | 110 (96.5) | 59 (100) | 128 (90.8) | 81 (55.9) | 108 (57.8) |
| <18 or >60 (%) | 4 (3.5) | 0 | 13 (9.2) | 64 (44.1) | 79 (42.2) |
| Group | |||||
| ATBa | 52 | 15 | 31 | 87 | 86 |
| Smear positive (%) | 44 (84.6) | 9 (60) | 11 (35.8) | 34 (39.1) | 33 (38.4) |
| Culture positive (%) | 46 (88.5) | 6 (40) | 25 (80.6) | nsc | ns |
| Nuclear positive (%) | 36 (69.2) | 14 (93.3) | 24 (77.4) | 52 (59.8) | 57 (66.3) |
| LTBI | 19 | 23 | 53 | 28 | 27 |
| HC | 43 | 21 | 57 | 30 | 41 |
| NTBb | 33 | ||||
| PN | 9 | ||||
| CA | 20 | ||||
| Fungi/pleural effusion | 4 | ||||
a
The detection rates of the three sputum-based methods were analyzed in parallel.
b
The NTB samples consist of PN, CA, and fungi/pleural effusion.
c
ns, no sample.